晚期非小细胞肺癌合并恶性气道梗阻的重复治疗性支气管镜模式与生存分析
基于SEER-Medicare数据库的回顾性队列分析纳入2006至2019年新诊断晚期NSCLC且诊断后6个月内因MAO接受治疗性支气管镜的≥66岁患者1092例,其中71.8%首次操作为腔内治疗。1年内重复操作比例为25.4%,首次重复操作中74.4%在30天内完成,重复操作比例从2006年的31.1%降至2017年的19.8%;中位OS为4.5个月,6个月、1年、2年OS分别为44.9%、29.8%、17.1%。
要点
- 晚期NSCLC合并MAO患者1年内重复治疗性支气管镜比例为25.4%,首次重复多发生在30天内。
- 腔内治疗是最常用的首次和重复操作方式,分别占71.8%和85.8%。
- 该人群预后差,中位OS仅4.5个月,2年OS为17.1%。
核心结论
- 约四分之一的晚期NSCLC合并MAO患者接受了重复治疗性支气管镜,且多数首次重复发生在初次操作后30天内。
- 该人群生存结局较差,需进一步探索以优化治疗机会。
研究设计与样本
- 回顾性队列分析,使用SEER-Medicare关联数据库,纳入2006至2019年新诊断晚期(III/IV期)NSCLC患者。
- 纳入年龄≥66岁、诊断后6个月内因MAO接受治疗性支气管镜的患者,共1092例(排除24例首次接受光动力治疗者)。
- 首次操作分类为腔内治疗、气道支架、气道支架联合腔内治疗或光动力治疗;分析重复操作模式及总生存(OS)。
主要发现
- 患者中48.9%为III期、51.1%为IV期;腔内治疗为最常见的首次支气管镜干预(71.8%)。
- 1年内重复操作比例为25.4%;在发生首次重复操作的患者中,74.4%在30天内完成。
- 重复操作最常采用腔内治疗(85.8%);重复操作比例从2006年的31.1%降至2017年的19.8%。
- 中位OS为4.5个月;6个月、1年、2年OS分别为44.9%、29.8%、17.1%。
临床怎么用
- 对晚期NSCLC合并MAO接受治疗性支气管镜的患者,应关注术后30天内重复操作的风险。
- 重复操作多采用腔内治疗,临床决策时可结合首次操作方式与患者预后进行个体化安排。
局限性
- 本研究为回顾性队列分析,仅纳入SEER-Medicare数据库中年龄≥66岁的患者,结果外推需谨慎。
- 原文未报告重复操作的相关因素分析结果及校正后生存比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant airway obstruction (MAO) is a common, debilitating complication in advanced lung cancer. Therapeutic bronchoscopy is successfully applied to manage MAO. MAO recurs and requires repeat procedures. RESEARCH QUESTION: What are the patterns of repeat therapeutic bronchoscopy, associated factors of repeat procedures, and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) and concurrent MAO? STUDY DESIGN AND METHODS: This retrospective cohort analysis used the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database for patients newly diagnosed with advanced-stage NSCLC (ie, stage III/IV) from 2006 to 2019. Patients aged ≥ 66 years with NSCLC who underwent therapeutic bronchoscopy for MAO within 6 months of diagnosis were identified using procedure codes. The index procedure was categorized as endoluminal therapy, airway stent, airway stent with endoluminal therapy, or photodynamic therapy. Postindex repeat procedure patterns, including incidence, time to first repeat procedure, and unadjusted repeat procedure trends, were examined. OS was assessed by using the Kaplan-Meier method from the date of index therapeutic bronchoscopy over 6 months, 1 year, and 2 years. RESULTS: A total of 1,092 patients (excluding 24 who received index photodynamic therapy) with advanced-stage NSCLC (48.9% stage III, 51.1% stage IV) and concurrent MAO were included. Endoluminal therapy was the common index bronchoscopy intervention (71.8%). Overall, the proportion of repeat procedure within 1 year was 25.4%. For those who underwent first repeat procedures, 74.4% had the procedure within 30 days. Endoluminal therapy was frequently used as the repeat procedure modality (85.8%). Repeat procedures decreased from 31.1% in 2006 to 19.8% in 2017. Overall, 6-month, 1-year, and 2-year OS were 44.9%, 29.8%, and 17.1%, with a median OS of 4.5 months. INTERPRETATION: This analysis showed that one-fourth of NSCLC patients with MAO underwent repeat therapeutic bronchoscopy, most occurring within 30 days following the initial procedure. Survival outcomes require further exploration to optimize therapeutic opportunities in this population.
引用
- Murgu SD, Zhou M, Laxmanan B, et al. Procedure Patterns and Survival in Advanced Non-Small Cell Lung Cancer With Malignant Airway Obstruction: A Surveillance, Epidemiology, and End Results Medicare Analysis. Chest. 2025. PMID: 40882700. doi:10.1016/j.chest.2025.07.4088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。